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1  | INTRODUC TION
1.1 | Clinical characterisation of obesity
Obesity is characterised as an accumulation of excess body fat 
that has a detrimental impact on health outcomes and is clinically 
defined based on the body mass index (BMI), measured as weight 
(kg) divided by height (meters) squared (kg/m2) (World Health 
Organization, 2000). The BMI is recommended by the World Health 
Organization (WHO) to clinically classify weight and determine clini-
cal risk (Table 1) (McPherson & Lane, 2015). Within this system, obe-
sity is defined as having a BMI of >30 kg/m2, while morbid obesity 
is defined as having a BMI of >35 kg/m2 (Okorodudu et al., 2010). 
However, the type and distribution of body fat accumulation are of 
clinical importance in the assessment of the risk of obesity-related 
complications (Alberti et al., 2009). In fact, BMI does not consider 
lean body mass and fat mass proportions, nor the distribution of det-
rimental visceral adiposity (white adipose tissue) and protective sub-
cutaneous adipose tissue. BMI is therefore considered to have a low 
sensitivity to appropriately determining adiposity and may underes-
timate or overestimate the risk of obesity in a significant proportion 
of the population (Okorodudu et al., 2010).
The use of body fat percentage provides insight into the lean and 
fat mass ratios, differentiated between genders. The accepted con-
sensus for increased risk of adiposity complications is >25% in males 
and >30% in females (Adler, Cassidy, Fricke, & Bonduriansky, 2013). 
Waist circumference, however, most closely reflects visceral adipos-
ity. It is measured around the abdomen at the mid-point between the 
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Abstract
Obesity is considered a global health problem affecting more than a third of the pop-
ulation. Complications of obesity include cardiovascular diseases, type 2 diabetes 
mellitus, malignancy (including prostatic cancer), neurodegeneration and accelerated 
ageing. In males, these further include erectile dysfunction, poor semen quality and 
subclinical prostatitis. Although poorly understood, important mediators of obesity 
that may influence the male reproductive system include hyperinsulinemia, hyperlep-
tinemia, chronic inflammation and oxidative stress. Obesity is known to disrupt male 
fertility and the reproduction potential, particularly through alteration in the hypo-
thalamic-pituitary-gonadal axis, disruption of testicular steroidogenesis and meta-
bolic dysregulation, including insulin, cytokines and adipokines. Importantly, obesity 
and its underlying mediators result in a negative impact on semen parameters, includ-
ing sperm concentration, motility, viability and normal morphology. Moreover, obe-
sity inhibits chromatin condensation, DNA fragmentation, increases apoptosis and 
epigenetic changes that can be transferred to the offspring. This review discusses 
the impact of obesity on the male reproductive system and fertility, including asso-
ciated mechanisms. Furthermore, weight management strategies, lifestyle changes, 
prescription medication, and complementary and alternative medicine in the man-
agement of obesity-induced subfertility is discussed.
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anterior superior iliac spine and lowest potion of the costal margin, 
and accepted cut-off values range from 88 to 94 cm depending on 
ethnicity and gender (Alberti et al., 2009). This is currently consid-
ered as the most sensitive clinical risk marker for adiposity-induced 
complications (World Health Organization, 2000).
Complications of obesity rise exponentially with visceral adipos-
ity. Common complications include cardiovascular disease (CVD), 
type 2 diabetes mellitus (T2DM) and various cancers, alongside 
accelerated ageing, neurodegeneration and a negative impact on 
human reproduction. These appear to be mediated through com-
plex and poorly understood mechanisms, including insulin resistance 
(hyperinsulinemia), hyperleptinemia, chronic systemic low-grade in-
flammation and oxidative stress, as illustrated in Figure 1 (Leisegang, 
Henkel, & Agarwal, 2019).
1.2 | Epidemiology of obesity
Obesity is considered a global health problem (Davidson, Millar, 
Jones, Fatum, & Coward, 2015), with a significant global increase 
reported between 1980 and 2013 in men (28%–36%) and women 
(29%–38%) (Ng et al., 2014). An estimated 1.4 billion people are cur-
rently considered as overweight or obese, including over 200 million 
obese males (Davidson et al., 2015). This is expected to increase to 
more than 40% of the global population by 2030 (Kelly, Yang, Chen, 
Reynolds, & He, 2008). In 2013, obesity was controversially recog-
nised as a disease by the American Medical Association (AMA), with 
a significant consensus that obesity is a pandemic that requires pre-
vention and management due to the co-morbidities and complica-
tions (Meldrum, Morris, & Gambone, 2017). This is predominantly 
driven by an obesogenic environment, mediated through energy-
dense food, high sugar intake, societal structure that reduces physi-
cal mobility and inexpensive nonphysical activities such as television, 
video games and social media (Meldrum et al., 2017).
1.3 | Risk factors
Polygenetic predisposition, particularly through single nucleotide 
polymorphisms (SNPs) and epigenetic inheritance, alongside age-
ing (mediated predominantly through oxidative stress) and female 
gender are considered as significant nonmodifiable risk factors of 
obesity (Leisegang, Henkel, & Agarwal, 2017). Other risk factors 
include poor socio-economic status, psychological factors and re-
duced quantity or quality of sleep (e.g. night-shift workers) (Haslam 
& James, 2005). Importantly, the most significant risk factor for obe-
sity is poor nutritional options (increased energy-dense foods) and a 
sedentary lifestyle within the context of an increasingly obesogenic 
and industrialised environment. (Castro, Macedo-de la Concha, & 
Pantoja-Meléndez, 2017). This is predominantly observed in so-
called ‘Westernized’ regions that are closely correlated with the 
obesity pandemic (Haslam & James, 2005). Numerous prescription 
medications are also associated with obesity risk, including thiazide 
diuretics and beta-blockers (hypertension), thiazolidinedione agents 
and insulin (type 2 diabetes mellitus), tricyclic and monoamine oxi-
dase inhibitors (antidepressants), anti-psychotics, oral contraceptive 
pills and glucocorticoids (Wofford, King, & Harrell, 2006). However, 
the mediators of obesity and related complications remain complex 
within an obesogenic environment (Leisegang et al., 2019) (Figure 1).
1.4 | Obesity: A key component of 
metabolic syndrome
Metabolic syndrome is defined as a cluster of metabolic derange-
ments that increases the risk for cardiovascular disease, type 2 dia-
betes mellitus and various malignancies, among other disorders. The 
most widely accepted diagnostic criterion requires the presence of 
three of the following five identified features: increased waist cir-
cumference (obesity), hypertension, low HDL-cholesterol, increased 
triglycerides and glucose intolerance. Cut-off values are different 
based on genetic predisposition and gender (Alberti et al., 2009). 
Obesity is just one of five diagnostic features, and therefore 
Author's Perspective
Key points
• Obesity is associated with reduced fertility potential in 
males.
• Increased visceral adiposity affects steroidogenesis and 
spermatogenesis locally (testicular dysfunction) and pe-
ripherally (hypogonadism, inflammation and oxidative 
stress).
• Sperm DNA integrity and epigenetic modifications are 
important considerations in obesity related infertility 
management.
• Metabolic co-morbidities such as hyperinsulinemia, 
hyperleptinemia, systemic inflammation and oxidative 
stress are important metabolic mediators of obesity in-
duced infertility in males.
• Improvement of adiposity improves fertility outcomes.
Potential areas of research
• The mechanisms of inflammation and oxidative stress in 
obesity related reproductive dysfunction?
• The potential role of antioxidants and immunomodu-
lation as a novel therapeutic strategy in male induced 
subfertility?
• Evidence based guidelines for obesity reduction to im-
prove fertility and ART outcomes?
• An optimal nutritional strategy to improve the impact of 
obesity on male reproductive system and fertility?
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normal-weight individuals could have metabolic syndrome, and con-
versely, patients who are considered as overweight and obese but do 
not have the metabolic syndrome phenotype, may be at a lower risk 
for its complications (Alberti et al., 2009).
The co-morbidities and complications of obesity and metabolic 
syndrome are similar. Co-morbidities include obstructive sleep 
apnea, nonalcoholic fatty liver disease (NAFLD), microvascular dis-
ease and vasoconstriction. Complications include CVD, T2DM, 
malignancy (including prostatic cancer), neurodegeneration and 
accelerated ageing (McPherson & Lane, 2015). In males, these fur-
ther include erectile dysfunction, poor semen quality and subclinical 
prostatitis (Leisegang et al., 2019). These complications are medi-
ated through common underlying mechanisms that are poorly un-
derstood, including metabolic, hormonal and immune dysfunctions 
such as insulin resistance (hyperinsulinemia), leptin resistance (hy-
perleptinemia), low-grade chronic inflammation and oxidative stress 
(Huang, 2009) (Figure 1). In males, obesity and metabolic syndrome 
are associated with hypogonadism as a common feature, thereby 
BMI Category Complication risk Complications
<18.5 Underweight Increased Immunodeficiency; infectious 
disease; malignancies
18.5–24.9 Optimal weight Low Uncommon
25.0–29.9 Overweight Mild CVD; T2DM; neurodegeneration; 
malignancies30.0–34.9 Obesity (Class I) Moderate
35.0–39.9 Obesity (Class II) Severe
>40 Obesity (Class III) Very severe
Abbreviations: CVD, cardiovascular disease; NCCDs, noncommunicable chronic diseases; T2DM, 
type 2 diabetes mellitus.
TA B L E  1   Body mass index (BMI) 
categories and risk of co-morbidities
F I G U R E  1   Risk factors, mechanisms 
and male reproductive outcomes in 
obesity. E2, 17β-oestradiol; T, testosterone
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further increasing the risk for infertility and perpetuating the un-
derlying mechanisms of obesity-induced complications (Du Plessis, 
Cabler, McAlister, Sabanegh, & Agarwal, 2010).
2  | IMPAC T OF OBESIT Y ON MALE 
REPRODUC TION
2.1 | Obesity and hormonal imbalances
2.1.1 | Hypothalamic-pituitary-gonadal axis
Physiological alterations induced by obesity that adversely affect the 
male reproductive endocrine system are mediated primarily through 
the hypothalamic-pituitary-gonadal (HPG) axis, the principal endo-
crine regulator of reproductive functions (Agarwal & Dutta, 2020; 
Dutta, Sengupta, & Muhamad, 2019). These HPG axis alterations are 
illustrated in Figure 1. Obesity is further associated with hypertro-
phy and hyperplasia of adipocytes, induction of adipokines secre-
tion thereby altering endocrine regulation and testicular functions 
(Dutta, Biswas, & Sengupta, 2019). In obese men, increased leptin 
secretion may also inhibit testosterone production by the Leydig 
cells (Caprio et al., 1999).
Increased adipose tissue depositions lead to an increased con-
version of testosterone to estradiol (Hammoud, Gibson, Peterson, 
Hamilton, & Carrell, 2006). This is mediated through excess produc-
tion and hyper-activity of the aromatase cytochrome P450 enzyme 
in white adipose tissue (Katib, 2015). Obesity parameters such as 
BMI, total body fat percentage, percentage of subcutaneous fat and 
intra-abdominal fat are inversely correlated with low testosterone 
and directly correlated with high oestrogen levels in males (Tsai, 
Matsumoto, Fujimoto, & Boyko, 2004).
The pulsatile release of hypothalamic gonadotropin-releasing 
hormone (GnRH) result in the secretion of anterior pituitary gonado-
tropins, follicle-stimulating hormone (FSH) and luteinising hormone 
(LH) (Blache, Zhang, & Martin, 2003). These gonadotropins are the 
key regulatory hormones acting upon the testicular cells. FSH acts 
upon the Sertoli cells to regulate spermatogenesis indirectly and 
stimulates synthesis of inhibin by the Sertoli cell. Inhibin acts directly 
through a negative feedback mechanism to downregulate pituitary 
FSH release. LH acts on the Leydig cells to upregulate steroidogen-
esis and testosterone synthesis. Testosterone further mediates 
spermatogenesis by its nuclear receptors in the Sertoli cell (Dutta, 
Sengupta, & Muhamad, 2019).
Both oestrogen and testosterone act via an indirect negative 
feedback loop to the hypothalamic arcuate nucleus, where they 
downregulate KISS1neurons that secrete kisspeptin, thereby in-
hibiting GnRH release. Kisspeptin is well known for its role in es-
tablishing a link between metabolic and reproductive functions of 
hypothalamic neuroendocrine pathways (Wolfe & Hussain, 2018). 
Besides stimulating GnRH release, kisspeptin is suggested to inhibit 
lipogenesis and induce lipolysis (Clarke, Dhillo, & Jayasena, 2015). 
Thus, in obesity, decreased hypothalamic expression of kisspeptin 
mRNA and KISS1may lead to suppressed pulsatile release of hy-
pothalamic GnRH, causing hypothalamic hypogonadism (Wolfe & 
Hussain, 2018).
2.1.2 | Testicular steroidogenesis
Obesity-induced impairment in the sex hormone levels leads to ad-
verse changes in testicular functions. Oestrogen is biologically more 
active than testosterone, therefore, a subtle increase in estradiol 
levels may have more of an inhibitory effect on testicular func-
tion compared with an increase in testosterone levels (Hammoud 
et al., 2006). Oestrogen regulates the overproduction of testoster-
one by limiting the levels of active testosterone in normal-weight 
men (Schulster, Bernie, & Ramasamy, 2016). Oestrogen receptor 
expression in the male hypothalamus indicates that increased oes-
trogen levels in obese men elicit the negative feedback mechanism 
to inhibit pulsatile GnRH release. This in turn leads to subsequent in-
sufficiency of LH and FSH for steroidogenesis and spermatogenesis 
(Chimento, Sirianni, Casaburi, & Pezzi, 2014). The elevated oestrogen 
and induced systemic inflammation may influence steroidogenesis in 
the Leydig cells. It is plausible that the proteins mediating cholesterol 
uptake into the mitochondria, such as the steroidogenic acute regu-
latory (StAR) protein, key steroidogenic enzymes (P450scc, 3βHSD 
and 17 βHSD) are negatively affected by increasing concentrations 
of inflammatory cytokines (Leisegang & Henkel, 2018). Inhibin B, 
a growth-like factor secreted by Sertoli cells, also inhibits FSH se-
cretion. Obese men have suppressed inhibin B production thereby 
disrupting the feedback loop of the HPG axis. This suggests that, 
besides impairment of steroidogenesis, obesity-mediated hormonal 
modulation has a direct adverse impact on the Sertoli cells (Salazar, 
Sánchez, Álvarez, Frusch, & Mejía, 2018).
2.1.3 | Metabolic hormone imbalances
Excess white adipose tissue contributes significantly to the altera-
tions in endocrine regulation leading to male reproductive dys-
function. Increased oestrogen levels together with the surge of 
an array of adipose tissue secretions interfere with the reproduc-
tive hormonal control over testicular functions (Bessesen, Hill, 
& Wyatt, 2004). Adipose tissues serve as a source of hormones, 
adipokines, pro-inflammatory cytokines, as well as endogenous 
and exogenous toxins. In obese men, major adipokines, such as 
adiponectin (Dutta, Sengupta, & Biswas, 2019), ghrelin (Álvarez-
Castro, Pena, & Cordido, 2013), leptin (Ahima, 2008), orexin (Perez-
Leighton, Butterick-Peterson, Billington, & Kotz, 2013), obestatin 
(Irez, Karkada, Dutta, & Sengupta, 2019) and inflammatory cytokines 
(Leisegang & Henkel, 2018) disrupt normal reproductive hormonal 
regulation.
Leptin, the key regulatory adipokine, is synthesised and secreted 
primarily in adipocytes and has a central function in the homoeosta-
sis of energy intake and expenditure. Positively correlated with body 
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fat mass, hyperleptinemia modulates male reproductive function 
(Malik, Durairajanayagam, & Singh, 2019; Sengupta, Bhattacharya, 
& Dutta, 2019). Despite the essentiality of leptin for normal repro-
ductive function, in excessive levels, it can severely affect male re-
production. The collective observations from studies in human and 
experimental animal suggest that leptin can serve to understand the 
possible association between infertility and obesity (Almabhouh, Aziz, 
Durairajanayagam, & Singh, 2020; Almabhouh, Md Mokhtar, et al., 
2020). Leptin may act via its receptors on the KISS1 neurons, stimu-
lating GnRH release from the hypothalamus. KISS1 neurons project to 
both GnRH neurons as well as to the NPY neurons (Ojeda et al., 2006). 
Thus, leptin can prevent GnRH inhibition by the NPY neurons, acting 
through KISS1. It is hypothesised that obese men may develop leptin 
resistance, which may lead to the suppression of KISS1 neuron activi-
ties and increased NPY levels, causing an inhibition of GnRH neurons 
(Ojeda et al., 2006). This eventually affects the release of gonado-
tropins from the pituitary, reducing steroidogenesis and resulting in 
hypogonadotropic hypogonadism (Teerds, Rooij, & Keijer, 2011).
It has also been reported that deficiency of the functional leptin 
gene may result in decreased gonadotropin secretion thereby affect-
ing fertility parameters, while exogenous leptin administration could 
significantly improve fertility (Mounzih, Lu, & Chehab, 1997). Leptin 
deficiency in mice has shown impaired spermatogenesis and high 
rates of germ cell apoptosis (Bhat et al., 2006). These evidences in-
dicate that leptin is vital for maintaining normal testicular activities. 
However, excessive leptin secretion in obese men inhibits testicular 
functions (Ramos & Zamoner, 2014), possibly by inducing uncontrolled 
production of reactive oxygen species (ROS) in endothelial cells by 
elevated mitochondrial fatty acid oxidation (Yamagishi et al., 2001).
In obese men, the levels of serum adiponectin are elevated and 
it bears an inverse association with testosterone (Page et al., 2005). 
In addition, orexin (hypocretin) which is one of the nonclassical met-
abolic hormones have been shown to stimulate testosterone pro-
duction by increasing the activities of the steroidogenic enzymes in 
Leydig cells (Zheng et al., 2014). Orexin also plays a role in amelio-
rating cellular oxidative damage (Duffy, Nixon, & Butterick, 2016). 
Obesity is associated with reduced levels of orexins and thereby dis-
rupts the balance between energy homoeostasis and reproductive 
functions in men (Sengupta, Dutta, Tusimin, & Karkada, 2019).
Resistin, an adipose tissue-specific secretory factor, is substan-
tially increased by obesity-induced excess adipose tissues. It report-
edly impairs the glucose uptake ability of the adipose cell, elevates 
blood glucose levels, and thereby reduces insulin sensitivity in obese 
men. There are studies that support that resistin can induce type 2 
diabetes in obese men (Flehmig et al., 2014).
Hyperinsulinemia in insulin-resistant obese men may cause de-
creased SHBG levels and testosterone levels which are needed for 
normal spermatogenesis. Hence, obese men suffering from type 2 
diabetes may acquire secondary hypogonadism. This may reflect 
direct effect of insulin resistance on testosterone synthesis by the 
Leydig cells (Du Plessis et al., 2010).
Ghrelin is a neuropeptide secreted in the gastrointestinal tract 
and is referred to as the ‘hunger hormone’. It has also been shown 
to be associated with impaired steroidogenesis and low serum tes-
tosterone levels (Wang et al., 2011). Its role in steroidogenesis is 
predicted via its receptor expressions in the testis, although any di-
rect effect of ghrelin on spermatogenesis has not yet been reported 
(Ishikawa, Fujioka, Ishimura, Takenaka, & Fujisawa, 2007). Increase in 
serum levels of ghrelin is associated with increased obesity-related 
complications (Dutta, Biswas, Sengupta, & Nwagha, 2019).
2.2 | Obesity and spermatogenesis
In the seminiferous tubules, there is a steady balance among 
germ cell growth, multiplication and apoptosis (Rooij, Alphen, & 
Kant, 1986). Following the first spermatogenic wave, the germ 
cells begin to differentiate in a distinctive hormonal micro-envi-
ronment. In cases of cell over-production, apoptosis is induced by 
activation of the Bcl-XL and Bax systems (Hikim & Swerdloff, 1999). 
Spermatogonial apoptosis takes place only under specific condi-
tions, and an array of regulatory genes determine its induction. 
A1spermatozoa have been shown to undergo a significantly in-
creased rate of apoptosis in conditions of obesity. According to 
recent studies, dysregulation of apoptosis induction in spermato-
genic cells is a major causative factor of male infertility (Garolla 
et al., 2013). Obesity may exaggerate the induction of apoptosis by 
impairing the conventional Bax and Bcl-2 homoeostasis, such that 
the expression of Bax is highly increased while Bcl-2 expression 
is suppressed. This leads to activation of downstream signalling 
caspases of the apoptotic pathway (Jia et al., 2018). Moreover, the 
state of hyperlipidemia also causes increased stress upon the endo-
plasmic reticulum, inducing further spermatogenic cell apoptosis by 
high expressions of binding immunoglobulin protein (BiP) (Li, Dong, 
Lan, Zhang, & Li, 2015).
2.3 | Obesity and semen quality
Male fertility semen parameters primarily include sperm con-
centration and total sperm count, motility, viability and morphol-
ogy, among others. Human semen quality serves as a predictor 
of male fertility, which is suggested to be declining in recent dec-
ades (Carlsen, Giwercman, Keiding, & Skakkebæk, 1992; Sengupta, 
Dutta, et al., 2018; Sengupta, Dutta, & Krajewska-Kulak, 2017). 
Overweight and obese males are reported to be associated mainly 
with an increased prevalence of oligozoospermia and azoospermia 
(Sermondade et al., 2013). Obesity potentially induces bodily al-
terations and hormonal modulations that adversely affect fertility 
parameters in men (Bieniek et al., 2016). Association of BMI with 
sperm functions have been studied extensively yet a complete un-
derstanding of the underlying mechanisms is still lacking (Chavarro, 
Toth, Wright, Meeker, & Hauser, 2010; Hammiche et al., 2011; 
Sermondade et al., 2013).
Compared to normal-weight men, obese men have a threefold 
higher probability of oligozoospermia (concentration <15 million/
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ml) (WHO, 2010). Chavarro et al. (2010) suggested that a high BMI 
(>25 kg/m2) in men corresponds to poor total sperm count. The ejac-
ulate volume is reduced with increased BMI (Jensen et al., 2004), and 
sperm motility and morphology are also severely impaired by obe-
sity (Kahn & Brannigan, 2017). These findings have been supported 
by other studies further emphasising the disruptive effects of obe-
sity on sperm functions (Davidson et al., 2015).
2.4 | Obesity and sperm DNA integrity
Obesity-induced alterations in sperm functions may be significantly 
associated with sperm DNA fragmentation (SDF). In obese men, 
sperm DNA integrity is adversely affected. Increased DNA fragmen-
tation index (DFI) (percentage of spermatozoon with high single- or 
double-strand breaks in nuclear DNA, in a semen sample) is report-
edly accompanied by high BMI, which demonstrate the association 
of obesity and SDF (Panner Selvam, Sengupta, & Agarwal, 2020). It 
is suggested that the BMI more than 25 kg/m2 corresponds to high 
sperm DFI. Obesity-induced testicular oxidative stress is a possible 
mechanism that can explain this scenario. Obesity may induce tes-
ticular OS via several potential mechanisms. Increase in fatty acid 
oxidation in mitochondria and peroxisome by adipose tissue accu-
mulation lead to higher generation of ROS. Thus, higher ROS medi-
ates oxidative damage to biomolecules that include lipids, proteins, 
and DNA. These cause oxidation of polyunsaturated fatty acids in 
sperm membrane, loss of mitochondrial membrane potential and sin-
gle- and double-strand SDF (Panner Selvam et al., 2020). Maintaining 
sperm DNA integrity is essential for spermatozoa fertilising abil-
ity and successful pregnancy outcomes (Benchaib et al., 2007). In 
addition to the conventional semen parameters, analysis of SDF 
provides better understanding of the male fertility status. The im-
portance of the SDF assay in male infertility cases has also been 
supported by the American Urological Association (AUA) and the 
European Association of Urology (EAU) guidelines (Jarow, Sigman, 
& Kolettis, 2011). Several reports have put forth possible clinical val-
ues for proper assessment of SDF in male infertility (Agarwal, Cho, & 
Esteves, 2016; Agarwal, Majzoub, et al., 2016).
2.5 | Obesity and erectile dysfunction
Obese men have a 1.5-fold increased chance of developing erectile 
dysfunction (ED) (Sarwer, Hanson, Voeller, & Steffen, 2018), which 
has been reported to have a positive correlation with male infertility 
(Du Plessis et al., 2010). Obesity may lead to erectile dysfunction by 
reduction in testosterone levels and eliciting a systemic inflamma-
tory condition via release of inflammatory cytokines (Seftel, 2006). 
These inflammatory mediators directly induce endothelial cell dys-
function and via nitric oxide pathway they may lead to male erectile 
dysfunction (Yu, Li, Li, Zhong, & Mao, 2017). Obesity is linked with 
several pathogenic conditions, such as diabetes, hypertension and 
dyslipidemia, which may be linked to the induction of ED (Shamloul 
& Ghanem, 2013). The exact mechanism of obesity-induced ED 
requires better understanding, especially in relevance to de-
creased libido, endocrine dysregulation and psychological disorders 
(Hammoud, Gibson, Peterson, Meikle, & Carrell, 2008).
3  | OBESIT Y-INDUCED GENETIC AND 
EPIGENETIC MODIFIC ATIONS
Excessive adiposity negatively impacts DNA integrity and epigenetic 
regulation across a range of tissues, including adipose tissue, hepatic 
tissues, skeletal muscle, pancreas, hypothalamus, prostate and tes-
tes (Martins, Majzoub, & Agawal, 2019). The altered testicular envi-
ronment, dominated by inflammation and oxidative stress, reduces 
semen quality, modifies sperm membrane, mitochondrial lipids and 
induces DNA damage (Liu & Ding, 2017). Particularly, a negative 
impact on spermatozoa chromatin condensation and DNA integrity 
has been reported, mediating a risk for pregnancy complications, 
such as spontaneous abortion and recurrent pregnancy loss, as well 
as an impact on assisted reproductive techniques (ART) outcomes 
(Leisegang, 2019; Leisegang et al., 2019). This is further observed 
in animal and human studies in males with metabolic syndrome 
(Leisegang, Bouic, & Henkel, 2016; Leisegang, Udodong, Bouic, & 
Henkel, 2014). Furthermore, the impact of epigenetic modification 
in sperm DNA in obese males is reported to increase the risk of obe-
sity and metabolic derangements, neurological disorders (includ-
ing attention deficit disorder) and various cancers in the offspring 
(Soubry et al., 2016). Although paternal epigenetic modification is 
known to be transferred to the next generation, causality has not 
yet been demonstrated.
Epigenetic modification is due to a reset in methylation marks 
which regulate gene expression (Figure 1). The process establishes 
paternal-specific methylation in the embryo development. This 
transfer of epigenetic modifications is also suggested to be through 
the action of noncoding RNA. Genes that undergo modification in 
paternal obesity include MEG3, NDN, SNRPN and SGCE/PEG10, 
which regulate foetal development and tumour growth (Soubry 
et al., 2016). However, limited pre-clinical evidence suggests that 
the epigenetic modifications are reversible with reduced adiposity 
(Setayesh et al., 2018).
4  | MECHANISMS IMPLIC ATED IN 
OBESIT Y-INDUCED MALE INFERTILIT Y
The complex pathophysiology of obesity involves chronic inflamma-
tory responses together with endocrine disruptions among others. 
An obesogenic environment with an excessive deposition of visceral 
adipose tissues induces a Th1-lymphocyte and M1-macrophage 
driven pro-inflammatory responses (Leisegang et al., 2019). This in-
flammatory response is characterised by modulation of cytokines, 
adipokines and myokines that adversely affect numerous tissues, 
including the hypothalamus, cardiac, hepatic, pancreas and testes. 
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Male infertility and hypogonadism are among the major co-mor-
bidities associated with obesity-induced systemic inflammation. 
Inflammatory mediators of this immune response include interleu-
kin (IL)-1β, IL6, IL8, IL12, tumour necrosis factor-alpha (TNFα), in-
terferon gamma (IFNγ), transforming growth factor-beta (TGFβ), 
macrophage inflammatory protein (MIP-1), monocyte chemotactic 
protein (MCP-1), and neuroendocrine hormones, leptin and resistin 
(Figure 2) (Leisegang et al., 2019).
Leptin induces macrophage infiltration in tissues further elicit-
ing the inflammatory responses. These may also lead to hypotha-
lamic inflammation thereby affecting the release of hypothalamic 
releasing hormones and dysregulation of the HPG axis (Castro 
et al., 2017). The pathways involved in obesity-induced inflamma-
tion has been reported to involve activation of toll-like receptor 4 
(TLR4), endoplasmic reticulum stress, mitochondrial dysfunction 
and serine/threonine kinase activation (Thaler & Schwartz, 2010). 
The dyslipidemia state in obese men may cause testicular oxida-
tive stress, which is a common established pathway for disrup-
tion of sperm functions (Biswas, D'souza, & Bhat, 2017). Cellular 
processes may modify LDL functions to render it capable to act 
as a ligand for macrophage pattern recognition receptors, such 
as the toll-like receptors (TLRs). Thus, it directly induces pro-in-
flammatory signalling pathways to initiate the release of the 
pro-inflammatory mediators. The modified LDL may also be en-
gulfed by monocytes, neutrophils and other macrophages, which 
lead to the accumulation of cholesterol in those cells. This further 
amplifies the TLR signalling cascades, worsening the inflamma-
tory condition (Tall & Yvan-Charvet, 2015). Obesity and metabolic 
syndrome may elicit reproductive tract inflammation owing to 
higher levels of pro-inflammatory cytokines as found in the pros-
tate, seminal vesicles, testes, epididymis and ejaculate of obese 
men (Leisegang et al., 2016). This inversely correlates with indi-
cators of hypogonadism and decreased semen quality (Leisegang 
et al., 2016). Moreover, hyperglycemia is another independent fac-
tor in the induction of oxidative stress and endoplasmic reticulum 
stress. This can cause inflammation that may result in glycation 
end-products and induce SDF (Maresch et al., 2017). C-reactive 
protein, another prominent inflammatory marker, is also markedly 
elevated in obesity-associated reproductive tract inflammation 
(Leisegang et al., 2019).
The obesity-associated inflammatory responses may disrupt the 
endocrine regulation of reproductive functions via affecting the 
HPG axis and its crosstalk with other hormones. The obesity-associ-
ated hormonal alterations mainly involve reduced levels of testoster-
one, progesterone and sex hormone-binding globulin (SHBG) levels 
and high levels of oestrogen that strongly inhibit the HPG axis so 
F I G U R E  2   Low-grade systemic chronic inflammation associated with obesity
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that the release of hypothalamic GnRH and subsequent release of 
FSH and LH are inhibited (Leisegang et al., 2016). Since obesity is 
associated with excessive adipose tissue deposition, the adipose tis-
sue-derived factors and several metabolic hormones also play a vital 
role in the modulation of hormonal crosstalk in obese men. Leptin re-
sistance is a common phenomenon in obesity, leading to inhibition of 
GnRH and the subsequent LH and FSH release (Ojeda et al., 2006). 
Impaired regulation of testicular functions by GnRH and gonadotro-
pin may explain the primary hormonal mechanism of obesity-asso-
ciated male infertility. In addition, obese men suffer from physical 
disorders such as erectile dysfunction and high scrotal temperature 
that also contribute to male infertility (Du Plessis et al., 2010).
5  | OBESIT Y AND ART OUTCOMES
Nongenetic effects of long-term paternal health issues may af-
fect the offspring by transmission via the male gamete (Soubry 
et al., 2013). Studies have reported that male obesity substantially 
affects the outcome of ARTs such as in vitro fertilisation (IVF) or 
intracytoplasmic sperm injection (ICSI). Rates of clinical pregnancy 
following ART are reduced in couples with an obese male partner 
(Schliep et al., 2015; Umul et al., 2015). The live birth rate follow-
ing ART mediated pregnancy is also reduced in the case of paternal 
obesity (Schliep et al., 2015; Umul et al., 2015). Moreover, obesity in 
the male partner has also been reported to affect the child's devel-
opment during infancy and early childhood period as reflected by 
the BMI growth curves from birth till the age of 3.5 years (Linabery 
et al., 2013). Thus, ART outcomes of couples with an obese male 
partner demonstrate decreased impregnation rate, live birth rates 
and compromised infant health.
6  | MANAGEMENT OF OBESIT Y-
A SSOCIATED MALE INFERTILIT Y
Management of obesity-associated male infertility is complex due 
to the underlying pathophysiology and associated co-morbidities. 
Importantly, weight management strategies based on lifestyle 
amendments are recommended. However, treatment with various 
nutraceuticals and herbal (phyto) supplements may be warranted. 
Additional options include surgical and potentially prescription med-
ications that either improve adiposity and/or improve the underly-
ing mediators of obesity-related complications and infertility (Singh, 
Pragasam, & Venkatesan, 2018).
6.1 | Lifestyle modifications
Reduced abdominal adiposity, independent of a change in BMI, 
has been demonstrated to reduce seminal oxidative stress and 
SDF (Håkonsen et al., 2011). In animal models, a reduction in pa-
ternal weight modifies metabolic derangements and reproductive 
parameters, improving embryo quality and foetal development. 
This further reduces the negative consequences on metabolic and 
fertility	parameters	 in	 the	offspring	 (Danielewicz,	Przybyłowicz,	&	
Przybyłowicz,	2018).
A modern obesogenic or ‘Westernized diet’ is characterised by 
high energy sugars and refined carbohydrates, high total fat and hy-
drolyzed fatty acids consumption, with low consumption of fruits, 
vegetables, fibre and beneficial fatty acids. This dietary pattern is as-
sociated with poor semen parameters and fertility outcomes, includ-
ing in healthy males (Salas-Huetos, Bulló, & Salas-Salvadó, 2017). 
Optimal diets, such as the Mediterranean and similar ‘prudent’ diets, 
are demonstrated to improve obesity-associated metabolic derange-
ments and male semen parameters. These diets include increased 
intake fruits, vegetables, favourable fatty acids (unsaturated and 
omega-3 polyunsaturated fatty acids), whole grains, fibre, as well as 
foods rich in antioxidants, micronutrients and other phytochemicals 
(Salas-Huetos et al., 2017). These nutrients are obtained from fruits 
and vegetables, seafood, oils, nuts and seeds. Importantly, these 
dietary patterns further correlate to improved fertility parameters 
across a range of BMI classifications, even in the absence of weight 
loss (Salas-Huetos et al., 2017).
Adherence to the Mediterranean diet improves sperm concen-
tration, motility and morphology in humans (Karayiannis et al., 2017), 
and diets rich in fruits, vegetables, antioxidants, nuts, seeds and fish 
showed improved semen parameters, in large observational studies 
(Gaskins, Colaci, Mendiola, Swan, & Chavarro, 2012). These dietary 
habits also improve DNA fragmentation, suggesting a benefit on 
embryo, foetal and offspring quality (Mir, Franken, Andrabi, Ashraf, 
& Rao, 2018). It is proposed that the benefits of these nutritional 
sources on male fertility are due to antioxidant-rich foods which 
modulate positively inflammation and oxidative stress. Important 
antioxidants that are beneficial in combating male obesity and its 
associated infertility include β-carotenes, vitamins C, D and E, folate, 
selenium, zinc, l-carnitine, acetyl-carnitine and lycopene. Deficiency 
of these micronutrients is associated with oxidative stress in males 
(Leisegang et al., 2019). Furthermore, obesity is paradoxically asso-
ciated with micronutrient deficiencies (MND) through nutrient-poor 
foods and the increased requirements for antioxidants. Common 
MND in obesity includes vitamin D, selenium, vitamin C, zinc, vi-
tamin B1, β-carotenes, folate and vitamin E (Alhashem et al., 2014). 
Supplementation with omega-3 fatty acids is reported to be associ-
ated with better testicular function (Jensen et al., 2020). However, 
there are currently no guidelines for optimal nutritional recommen-
dations or antioxidant use in males across a range of BMI, although 
appropriate nutritional advice based on the Mediterranean diet for 
example, is warranted in the management of all male infertility cases.
Antioxidant-rich nutrition as described above is recommended 
as a primary source of the relevant antioxidants and micronutrients. 
However, the use of supplementation of specific or combined anti-
oxidant treatments may also be considered. The aim of any supple-
mentation is to restore appropriate redox balance without inducing 
reductive stress (Maneesh & Jayalekshmi, 2006). The use of antioxi-
dants in male reproduction, however, requires further investigation, 
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as there is no consensus of the type, dosage and duration of treat-
ment (Deepinder, Cocuzza, & Agarwal, 2008). Evidence suggests that 
antioxidant treatment reduces DNA damage, improves fertility and 
ART outcomes (up to 4-times improvement), and reduces the risk of 
pregnancy complications and spontaneous abortions (Mora-Esteves 
& Shin, 2013). Evidence further suggests that antioxidant treat-
ment can improve fertility outcomes in obesity, mediated through 
improved semen parameters, endocrine regulation, immunomodula-
tion and redox balance, independently of BMI and adiposity changes 
(Montanino Oliva, Minutolo, Lippa, Iaconianni, & Vaiarelli, 2016). 
Antioxidants more commonly used in studies for male reproduc-
tion include vitamin A (β-carotenes), B-vitamins, vitamin C (ascorbic 
acid) and E, coenzyme Q10, l-carnitine, α-lipoic acid, glutathione, N-
acetyl-cysteine, selenium, zinc and copper (Roychoudhury, Agarwal, 
Virk, & Cho, 2017). The application of phytonutrients through ap-
propriate medicinal herbs provide various secondary plant metabo-
lites that benefit human health, including obesity and male fertility 
(Leisegang et al., 2017). Phytonutrients that show benefit in obesity 
and male fertility include Camellia sinensis (epigallocatechingallate), 
Curcuma longa (curcuminoids), Nigella sativa (thymoquinone), Panax 
ginseng and Panax quinquefolius (ginsengosides), Vitus vinifera (resver-
atrol) and Withania somnifera (withanolides) (Leisegang et al., 2019; 
Payab et al., 2019; Roychoudhury et al., 2017; Sengupta, Agarwal, 
et al., 2018.
Physical exercise is a critical and cost-effective strategy to man-
age obesity and co-morbidities, further improving overall health 
and sense of well-being (Sansone et al., 2018). However, excessive 
intensity or duration of exercise can be detrimental on male repro-
ductive outcomes (Sansone et al., 2018). Exercise induces a rapid 
rise in testosterone, through increased pituitary activity, improved 
Leydig cell function and a reduction in testosterone clearance. 
However, excessively intense short-term and long-term exercise 
results in a reduction in serum testosterone over time (Sansone 
et al., 2018). Moderate exercise further improves sexual function 
and satisfaction in obese men, where increased fitness correlated 
with sexual desire and satisfaction. In fact, exercise is recom-
mended as first-line treatment in erectile dysfunction (Shamloul & 
Ghanem, 2013). This is relevant in the requirement for intercourse 
in natural conception (Sansone et al., 2018). Endurance exercise 
in obese rats reportedly improves visceral and epididymal adi-
posity, serum testosterone and gonadotropins, serum leptin and 
ghrelin, semen parameters and testicular oxidative stress (through 
increased superoxide dismutase and glutathione expression and 
reduction in thiobarbituric acid reactive substances) (Alhashem 
et al., 2014). Low-to-moderate exercise in obese fathers further 
mitigates the negative impact of epigenetic transfer to the off-
spring in rat models (McPherson & Lane, 2015). Moderate en-
durance exercise in obese males is suggested to improve fertility 
parameters, including oxidative stress and DNA damage in sper-
matozoon. However, intense exercise is not recommended (Du 
Plessis et al., 2010). More recently, caloric restriction (CR) has 
gained attention in obesity and metabolic syndrome patients, as 
well as general health and wellness. This is defined as a reduction 
in total calorie (energy) intake that does not result in MND (Moatt, 
Nakagawa, Lagisz, & Walling, 2016). In all mammals, including 
humans, CR has been demonstrated to increase lifespan through 
reduced age-related degeneration, as well as weight loss and im-
proved metabolic regulation in obesity. CR also reduces the risk 
of complications such as CVD, T2DM, malignancies and neurode-
generation (Moatt et al., 2016). Although the mechanisms remain 
poorly understood, a significant contributor is the upregulation 
of endogenous antioxidant production and improved redox reg-
ulation through the ageing process (Barja, 2014). Importantly, the 
impact of CR in male fertility is not clear, with initial evidence sug-
gesting a trade-off between longevity and reproduction potential 
in CR. However, long-term (5–7 years) CR investigation in Rhesus 
monkeys do not show any detrimental effect to semen parameters 
or reproductive hormones (Sitzmann et al., 2014). Therefore, stud-
ies in humans to determine the impact of CR on male reproduction 
in lean and obese males are warranted, although caution should be 
advised when using this approach based on the current evidence 
(Sitzmann et al., 2014).
6.2 | Prescription medication
Metformin is used in the management of insulin resistance and type 2 di-
abetes mellitus. Although some data are conflicting, evidence suggests 
that metformin provides benefit to male fertility (Ferreira et al., 2015). 
Metformin is associated with an improvement in semen parameters 
and fertility outcomes, including testicular weight and increased 
numbers of spermatogonia, Sertoli and Leydig cells. This is mediated 
through reduced apoptosis, protection against testicular inflammation 
and oxidative stress, and activation of the mitogen-activated protein 
kinase (MAPK) pathway (Ferreira et al., 2015; Ye et al., 2019).
Testosterone replacement therapy (TRT) improves obesity 
and metabolic-associated derangements and co-morbidities 
(Roth, Amory, & Page, 2008), including immune modulation, re-
duced oxidative stress, improved insulin and leptin sensitivity, 
reduced adiposity and increased lean body mass (Winter, Zhao, 
& Lee, 2014). However, excessive testosterone has a detrimen-
tal impact on spermatogenesis, primarily through the negative 
hormonal feedback. Therefore, TRT is not recommended for 
management of obese patients with desire for fertility (Roth 
et al., 2008; Winter et al., 2014). An alternative medication for 
improvement of hypogonadism in obese males is aromatase in-
hibitor (such as Letrozole and Anastrozole), which suppress the 
conversion of testosterone to oestrogen that is upregulated in 
obesity (Stephens & Polotsky, 2013). These medications are as-
sociated with improved spermatogenesis and semen parameters; 
however, approval for use in male infertility is currently lacking 
(Roth et al., 2008). Clomiphene citrate (selective oestrogen re-
ceptor modulator) has been reported to improve testosterone in 
hypogonadal obese males (Bendre, Murray, & Basaria, 2015; Ring, 
Lwin, & Köhler, 2016). Human chorionic gonadotropic (hCG), a LH 
analog, has been reported to increase intratesticular and serum 
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testosterone levels and maintain spermatogenesis in hypogonadal 
men, although the impact on adiposity in males is not clear (Ring 
et al., 2016).
6.3 | Surgical interventions
Although bariatric surgery has a significant effect on BMI, abdominal 
adiposity and metabolic derangements in obesity and metabolic syn-
drome, current evidence does not suggest a positive impact on male 
fertility parameters (Wei, Chen, & Qian, 2018). In fact, bariatric sur-
gery is suggested to potentially worsen semen parameters, where 
azoospermia and oligoasthenoteratozoospermia have been reported 
in the months following the procedure (di Frega, Dale, Matteo, & 
Wilding, 2005; Sermondade et al., 2012). This may be induced by 
the release of lipophilic toxic substances due to rapid weight loss, 
which include endocrine disrupters stored in the excess adipose 
tissue through environmental exposures (Reis & Dias, 2012; Wei 
et al., 2018). However, the medium and long-term impact of bariat-
ric surgery on male reproduction requires further investigation (Wei 
et al., 2018).
7  | CONCLUSION
Alongside the declining global trend in male infertility, obesity 
has been significantly increasing over recent decades. Obesity is 
known to adversely affect male infertility through alteration in 
semen parameters (including sperm concentration, motility, vi-
ability, morphology, DNA integrity and mitochondrial function), 
endocrine changes (including hypogonadism, hyperinsuinemia 
and hyperleptinemia) and systemic and reproductive system 
inflammation and oxidative stress. An obesogenic environment 
may elicit inflammatory responses, where adipokines such as 
leptin modulate the HPG axis and male reproductive functions. 
Induction of oxidative stress is suggested to be a common path-
way leading to disrupted male reproductive functions in obesity. 
In addition, obese men possess higher oestrogen than testoster-
one levels owing to increased aromatase activities, or by negative 
feedback mechanism of oestrogen to inhibit the pulsatile GnRH 
release and subsequent release of LH and FSH. Obesity further 
induces sperm DNA damage, resulting in increased apoptosis, 
DNA fragmentation and epigenetic transfer to the offspring. 
Male obesity is also associated with reduced success in ART in 
clinical practice. Importantly, correction of obesity is suggested 
to reverse the impact on the male reproductive system. This is 
done through improved nutritional quality, increased appropri-
ate exercise, consideration of micronutrient and phototherapy 
supplementation. Medical intervention can be considered, par-
ticular strategies to improves testosterone and oestrogen ratios 
such as aromatase inhibitors and selective oestrogen receptor 
modulators.
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